Ethical and legal conflicts in the use of drug eluting stents in Brazil. Analysis of the major controversies for the adoption of this technology in public and private health care systems in this country;Conflitos éticos e judiciais no emprego dos stents farmacológicos no Brasil. Análise das principais controvérsias para incorporação dessa tecnologia nos sistemas de saúde público e privado no país

Revista Brasileira de Cardiologia Invasiva

Volumn 17, Issue 1, 2009, Pages 117-132

  Lopes, Marcelo Antônio Cartaxo Queiroga ^a,f   Lopes Filho, Marcelo Antonio Cartaxo Queiroga ^b,c   Gubolino, Luiz Antonio ^d   Mattos, Luiz Alberto ^e   Marin Neto, José Antonio ^b  

^a Hospital Santa Paula   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF MUNICH   (Germany)

^d Hospital Fornecedores de Cana   (Brazil)

^e INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^f Faculdade de Medicina de Ribeirão Preto ^*  (Brazil)

Author keywords

Angioplasty, transluminal, percutaneous coronary; Drug eluting stents; Ethics; Judicial power; Prostheses and implants

Indexed keywords

ARTICLE; BRAZIL; DRUG ELUTING STENT; ETHICAL DECISION MAKING; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; LEGAL ASPECT; PERCUTANEOUS CORONARY INTERVENTION;

EID: 66449125308     PISSN: 01041843     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Gruentzig AR, Myler RK, Hanna ES, Turina MI. Coronary transluminal angioplasty. Circulation. 1977;56(Supl 3):III-84.
2. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandablestent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994;331(8):489-495 (Pubitemid 24256751)
3. Kastrati A, Schömig A, Elezi S, Schühlen H, Dirschinger J, Hadamitzky M, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol. 1997;30(6):1428-1436 (Pubitemid 27486458)
4. Serruys PW, Kay IP, Disco C, Deshpande NV, de Feyter PJ. Periprocedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six months: results of a meta-analysis of the Belgian Netherlands Stent study (BENESTENT) I, BENESTENT II Pilot, BENESTENT II and MUSIC (Multicenter Ultrasound Stent In Coronaries) trials. J Am Coll Cardiol. 1999;34(4):1067-1074
5. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346(23):1773-1780 (Pubitemid 34586912)
6. Serruys PW, Ong AT, van Herwerden LA, Sousa JE, Jatene A, Bonnier JJ, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol. 2005;46(4):575-581 (Pubitemid 41132680)
7. Mercado N, Wijns W, Serruys PW, Sigwart U, Flather MD, Stables RH, et al. One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: a meta-analysis of individual patient data from randomized clinical trials. J Thorac Cardiovasc Surg. 2005;130(2):512-519 (Pubitemid 41074186)
8. Sousa JE, Costa MA, Abizaid A, Feres F, Seixas AC, Tanajura LF, et al. Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents. Circulation. 2005;111(18):2326-2329 (Pubitemid 40647068)
9. Marroquin OC, Selzer F, Mulukutla SR, Williams DO, Vlachos HA, Wilensky RL, et al. A comparison of bare metal and drug-eluting stents for off-label indications. N Engl J Med. 2008;358(4):342-352
10. Polanczyk CA, Wainstein MV, Ribeiro JP. Custo-efetividade dos stents recobertos com rapamicina em procedimentos percutâneos coronarianos no Brasil. Arq Bras Cardiol. 2007;88(4):464-474
11. Araújo DV, Lima VC, Ferraz MB. Análise de impacto do stent farmacológico no orçamento do Sistema Único de Saúde. Arq Bras Cardiol. 2007;88(4):458-463 (Pubitemid 46883845)
12. Kfouri Neto M. Responsabilidade civil do médico. 4a ed. São Paulo: Editora Revista dos Tribunais; 2001.
13. Mattos LA, Lemos Neto PA, Rassi A Jr, Marin-Neto JA, Sousa AGMR, Devito FS, et al. Diretrizes da Sociedade Brasileira de Cardiologia - Intervenção Coronária Percutânea e Métodos Adjuntos em Diagnóstico em Cardiologia Intervencionista (II Edição - 2008). Arq Bras Cardiol. 2008;91(6 Supl 1):1-58.
14. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349(14):1315-1323 (Pubitemid 37186209)
15. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370(9591):937-948 (Pubitemid 47393576)
16. Mauri L, Silbaugh TS, Garg P, Wolf RE, Zelevinsky K, Lovett A, et al. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med. 2008;359(13):1330-1342
17. Rothwell PM. External validity of randomised controlled trials: "To whom do the results of this trial apply?". Lancet. 2005;365(9453):82-93.
18. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364(9444):1519-1521 (Pubitemid 39410418)
19. Serruys PW, Daemen J. Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents. Circulation. 2007;115(11):1433-1439
20. http://www.fda.gov/ohrms/dockets/ac/06/minutes/2006-4253m1-quicksum.pdf. Acesso em 6 de fevereiro de 2009.
21. Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol. 2007;49(6):734-739 (Pubitemid 46210116)
22. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356(10):989-997 (Pubitemid 46376799)
23. Garcia B. Instituições de direito penal. 3a ed. São Paulo: Max Limonad; 1956. Vol.I. Tomo II. p.259.
24. Dibra A, Kastrati A, Alfonso F, Seyfarth M, Pérez-Vizcayno MJ, Mehilli J, et al. Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials. J Am Coll Cardiol. 2007;49(5):616-623 (Pubitemid 46177448)
25. Hoye A, Iakovou I, Ge L, van Mieghem CA, Ong AT, Cosgrave J, et al. Long-term outcomes after stenting of bifurcation lesions with the "crush" technique: predictors of an adverse outcome. J Am Coll Cardiol. 2006;47(10):1949-1958
26. Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA. 2004;292(22):2727-2734 (Pubitemid 39628251)
27. Gubolino LA, Mangione JA, Silva SS, Marin-Neto JA, Lopes MACQ, Salvadori Junior D, et al. Diretrizes da Sociedade Brasileira de Cardiologia sobre Qualidade Profissional e Institucional, Centro de Treinamento e Certificação Profissional em Hemodinâmica e Cardiologia Intervencionista (II Edição - 2008). Rev Bras Cardiol Invas. 2008;16(Supl 3):8-32.
28. http://usuarios.cultura.com.br/jmrezende/ Acesso em 6 de fevereiro de 2009.
29. Trindade IS. Stent é realmente um epônimo? Rev Bras Cardiol Invas. 2003;11(4):64-66
30. Häberle P. Hermenêutica constitucional - a sociedade aberta dos intérpretes da constituição: constituição para e procedimental da constituição. Tradução Mendes GF. Porto Alegre: Sérgio Antônio Fabris; 1997.
31. Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation. 1998;97(6):596-601. (Pubitemid 28090690)
32. Sanderson JE, Mayosi B, Yusuf S, Reddy S, Hu S, Chen Z, et al. Global burden of cardiovascular disease. Heart. 2007;93(10):1175. (Pubitemid 47492896)
33. Rassi A Jr. Análise econômica dos stents coronarianos farmacológicos no Brasil: para todos ou para poucos pacientes? Arq Bras Cardiol. 2007;88(4):376-377
34. Cardoso CO, Quadros AS, Mattos LA, Gottschall CA, Sarmento-Leite RE, Marin-Neto JA. Perfil de uso dos stents farmacológicos no Brasil: dados da Central Nacional de Intervenções Cardiovasculares (CENIC). Arq Bras Cardiol. 2007;89(6):356-361
35. DeVito FS, Marin-Neto JA, Mattos LA. Análise comparativa da intervenção coronária percutânea com stents farmacológicos versus stents não-farmacológicos na vigência de infarto do miocárdio com supradesnivelamento do segmento ST: dados do Registro Brasileiro CENIC. Rev Bras Cardiol Invas. 2008;16(4):456-462
36. Reale M. Código de ética médica. São Paulo: Editora Revista dos Tribunais; 1977. Vol.503. p.47.
37. Teixeira SF. Direito & medicina: aspectos jurídicos da medicina. Belo Horizonte: Del Rey; 2000.